MedTrace Logo

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

NCT06338683 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2024-03-29

No results posted yet for this study

Summary

This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.

Conditions

Interventions

DRUG

Olanzapine 2.5 MG

Oral olanzapine 2.5 mg once daily at bedtime until disease progression

DRUG

Standard anti-tumor treatment

Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation

DIETARY_SUPPLEMENT

Nutritional advice

All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition

Sponsors & Collaborators

  • Qinghai Red Cross Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2027-03-20
Completion
2028-03-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06338683 on ClinicalTrials.gov